Genetic Testing for Hydatidiform Moles

This page provides information on the new item which is introduced for genetic testing for hydatidiform moles on 1 November 2021.

Page last updated: 04 November 2021

From 1 November 2021, a new Medicare benefits Schedule (MBS) item will be available for genetic testing for hydatidiform moles, to determine the presence of and inform the management of these benign or malignant growths in pregnancies.

Genetic testing on a piece of tissue from a hydatidiform mole can help doctors provide women with targeted treatment and advice. The new item is for the analysis of products of conception from a patient with suspected hydatidiform moles for the characterisation of ploidy status.

PDF version Genetic testing for hydatidiform moles (PDF 201 KB)
Word version Genetic testing for hydatidiform moles (Word 88 KB)

In this section